Literature DB >> 8597275

Comparative treatment of experimental Staphylococcus aureus endophthalmitis.

H E Aguilar1, T A Meredith, C Drews, H Grossniklaus, A D Sawant, S Gardner.   

Abstract

PURPOSE: To compare treatment strategies for Staphylococcus aureus endophthalmitis, we created an animal model in an aphakic rabbit eye and tested six different approaches to treatment.
METHODS: Rabbit eyes were rendered aphakic, and three weeks postoperatively, S. aureus organisms were injected into the vitreous cavity. One group was maintained as a control. Twenty-four hours after bacterial injection, six different treatment groups were created for comparison. Clinical inflammation scores, culture results 48 hours after treatment, histopathologic gradings, and development of total corneal opacity three weeks after treatment were assessed.
RESULTS: Injection of vancomycin hydrochloride into the vitreous cavity was more effective than injection of cefazolin sodium (P = .01) in reducing the percentage of eyes that had positive culture results and also resulted in lower inflammation scores. Vitrectomy plus injection of either antibiotic was more effective than injection of the same antibiotic alone in reducing culture-positive results and reducing clinical inflammation scores. addition of systemic corticosteroids to intravitreal antibiotic injection did not improve any measure of outcome. Vitrectomy and injection of intravitreal vancomycin was the most effective strategy to sterilize the vitreous cavity, resulting in the lowest inflammation scores and the smallest percentage of eyes with opaque corneas.
CONCLUSION: In an animal model of S. aureus endophthalmitis, the combination of vitrectomy and injection of intraocular vancomycin was the most effective strategy for rapidly controlling the infective process and improving the outcomes measured three weeks after treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8597275     DOI: 10.1016/s0002-9394(14)70280-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Efficacy of vitrectomy in improving the outcome of Bacillus cereus endophthalmitis.

Authors:  Michelle C Callegan; Scott Guess; Nanette R Wheatley; Dustin C Woods; Gabe Griffin; Brandt J Wiskur; Robert Leonard
Journal:  Retina       Date:  2011-09       Impact factor: 4.256

2.  Intraocular dexamethasone produces a harmful effect on treatment of experimental Staphylococcus aureus endophthalmitis.

Authors:  T A Meredith; H E Aguilar; C Drews; A Sawant; S Gardner; L A Wilson; H E Grossniklaus
Journal:  Trans Am Ophthalmol Soc       Date:  1996

Review 3.  Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions.

Authors:  Michelle C Callegan; Michael Engelbert; David W Parke; Bradley D Jett; Michael S Gilmore
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

4.  Acute bacterial endophthalmitis after cataract extraction: results of treatment.

Authors:  M F Versteegh; J M Hooymans; V W De Lavalette; G Van Rij
Journal:  Doc Ophthalmol       Date:  2000       Impact factor: 2.379

Review 5.  Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions.

Authors:  Michelle C Callegan; Michael S Gilmore; Meredith Gregory; Raniyah T Ramadan; Brandt J Wiskur; Andrea L Moyer; Jonathan J Hunt; Billy D Novosad
Journal:  Prog Retin Eye Res       Date:  2007-01-22       Impact factor: 21.198

6.  Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis.

Authors:  Dennis P Han
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 7.  Recent Updates on Treatment of Ocular Microbial Infections by Stem Cell Therapy: A Review.

Authors:  Seoh Wei Teh; Pooi Ling Mok; Munirah Abd Rashid; Mae-Lynn Catherine Bastion; Normala Ibrahim; Akon Higuchi; Kadarkarai Murugan; Rajan Mariappan; Suresh Kumar Subbiah
Journal:  Int J Mol Sci       Date:  2018-02-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.